vs

Side-by-side financial comparison of National Vision Holdings, Inc. (EYE) and RxSight, Inc. (RXST). Click either name above to swap in a different company.

National Vision Holdings, Inc. is the larger business by last-quarter revenue ($487.3M vs $32.6M, roughly 14.9× RxSight, Inc.). National Vision Holdings, Inc. runs the higher net margin — 0.7% vs -28.1%, a 28.8% gap on every dollar of revenue. On growth, National Vision Holdings, Inc. posted the faster year-over-year revenue change (7.9% vs -18.9%). National Vision Holdings, Inc. produced more free cash flow last quarter ($30.3M vs $-2.3M). Over the past eight quarters, National Vision Holdings, Inc.'s revenue compounded faster (7.6% CAGR vs 5.1%).

Vision Research is an international company that manufactures high-speed digital cameras based in Wayne, New Jersey. Their cameras are marketed under the Phantom brand, and are used in a broad variety of industries including: defense, industrial product development, manufacturing, automotive, scientific research, and entertainment. Vision Research is a business unit of the Materials Analysis Division of Ametek Inc., a global manufacturer of electronic instruments and electromechanical devices.

RxSight, Inc. is a medical technology company focused on developing and commercializing innovative intraocular lens solutions for patients undergoing cataract and refractive lens exchange procedures. Its flagship Light Adjustable Lens allows post-surgery power adjustment via a dedicated light delivery device, serving global ophthalmology care markets to improve post-operative visual outcomes for patients.

EYE vs RXST — Head-to-Head

Bigger by revenue
EYE
EYE
14.9× larger
EYE
$487.3M
$32.6M
RXST
Growing faster (revenue YoY)
EYE
EYE
+26.8% gap
EYE
7.9%
-18.9%
RXST
Higher net margin
EYE
EYE
28.8% more per $
EYE
0.7%
-28.1%
RXST
More free cash flow
EYE
EYE
$32.5M more FCF
EYE
$30.3M
$-2.3M
RXST
Faster 2-yr revenue CAGR
EYE
EYE
Annualised
EYE
7.6%
5.1%
RXST

Income Statement — Q3 2026 vs Q4 2025

Metric
EYE
EYE
RXST
RXST
Revenue
$487.3M
$32.6M
Net Profit
$3.4M
$-9.2M
Gross Margin
77.5%
Operating Margin
2.0%
-34.8%
Net Margin
0.7%
-28.1%
Revenue YoY
7.9%
-18.9%
Net Profit YoY
139.8%
-54.1%
EPS (diluted)
$0.04
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EYE
EYE
RXST
RXST
Q4 25
$32.6M
Q3 25
$487.3M
$30.3M
Q2 25
$486.4M
$33.6M
Q1 25
$510.3M
$37.9M
Q4 24
$437.3M
$40.2M
Q3 24
$451.5M
$35.3M
Q2 24
$451.7M
$34.9M
Q1 24
$482.8M
$29.5M
Net Profit
EYE
EYE
RXST
RXST
Q4 25
$-9.2M
Q3 25
$3.4M
$-9.8M
Q2 25
$8.7M
$-11.8M
Q1 25
$14.2M
$-8.2M
Q4 24
$-28.6M
$-5.9M
Q3 24
$-8.5M
$-6.3M
Q2 24
$-3.1M
$-6.1M
Q1 24
$11.7M
$-9.1M
Gross Margin
EYE
EYE
RXST
RXST
Q4 25
77.5%
Q3 25
79.9%
Q2 25
74.9%
Q1 25
74.8%
Q4 24
71.6%
Q3 24
71.4%
Q2 24
69.5%
Q1 24
70.1%
Operating Margin
EYE
EYE
RXST
RXST
Q4 25
-34.8%
Q3 25
2.0%
-40.1%
Q2 25
3.4%
-41.6%
Q1 25
5.1%
-28.2%
Q4 24
-5.8%
-21.5%
Q3 24
-2.0%
-26.1%
Q2 24
0.1%
-23.9%
Q1 24
4.9%
-36.2%
Net Margin
EYE
EYE
RXST
RXST
Q4 25
-28.1%
Q3 25
0.7%
-32.4%
Q2 25
1.8%
-35.0%
Q1 25
2.8%
-21.6%
Q4 24
-6.5%
-14.8%
Q3 24
-1.9%
-17.9%
Q2 24
-0.7%
-17.4%
Q1 24
2.4%
-30.8%
EPS (diluted)
EYE
EYE
RXST
RXST
Q4 25
$-0.22
Q3 25
$0.04
$-0.24
Q2 25
$0.11
$-0.29
Q1 25
$0.18
$-0.20
Q4 24
$-0.36
$-0.14
Q3 24
$-0.11
$-0.16
Q2 24
$-0.04
$-0.16
Q1 24
$0.15
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EYE
EYE
RXST
RXST
Cash + ST InvestmentsLiquidity on hand
$56.0M
$228.1M
Total DebtLower is stronger
$236.5M
Stockholders' EquityBook value
$858.8M
$275.7M
Total Assets
$2.0B
$311.8M
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EYE
EYE
RXST
RXST
Q4 25
$228.1M
Q3 25
$56.0M
$227.5M
Q2 25
$48.5M
$227.5M
Q1 25
$80.0M
$229.3M
Q4 24
$73.9M
$237.2M
Q3 24
$81.2M
$237.1M
Q2 24
$179.5M
$233.3M
Q1 24
$150.1M
$125.4M
Total Debt
EYE
EYE
RXST
RXST
Q4 25
Q3 25
$236.5M
Q2 25
$255.6M
Q1 25
$244.7M
Q4 24
$248.6M
Q3 24
$252.8M
Q2 24
$143.9M
Q1 24
$448.6M
Stockholders' Equity
EYE
EYE
RXST
RXST
Q4 25
$275.7M
Q3 25
$858.8M
$276.0M
Q2 25
$850.6M
$278.0M
Q1 25
$836.2M
$279.3M
Q4 24
$816.3M
$281.2M
Q3 24
$840.0M
$277.3M
Q2 24
$843.4M
$275.2M
Q1 24
$841.3M
$163.9M
Total Assets
EYE
EYE
RXST
RXST
Q4 25
$311.8M
Q3 25
$2.0B
$308.5M
Q2 25
$2.0B
$309.0M
Q1 25
$2.0B
$313.0M
Q4 24
$2.0B
$318.6M
Q3 24
$2.0B
$310.5M
Q2 24
$2.1B
$305.5M
Q1 24
$2.2B
$183.2M
Debt / Equity
EYE
EYE
RXST
RXST
Q4 25
Q3 25
0.28×
Q2 25
0.30×
Q1 25
0.29×
Q4 24
0.30×
Q3 24
0.30×
Q2 24
0.17×
Q1 24
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EYE
EYE
RXST
RXST
Operating Cash FlowLast quarter
$46.6M
$-1.1M
Free Cash FlowOCF − Capex
$30.3M
$-2.3M
FCF MarginFCF / Revenue
6.2%
-6.9%
Capex IntensityCapex / Revenue
3.4%
3.5%
Cash ConversionOCF / Net Profit
13.83×
TTM Free Cash FlowTrailing 4 quarters
$83.0M
$-19.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EYE
EYE
RXST
RXST
Q4 25
$-1.1M
Q3 25
$46.6M
$-1.2M
Q2 25
$54.3M
$-4.4M
Q1 25
$32.2M
$-8.8M
Q4 24
$30.3M
$-4.3M
Q3 24
$27.9M
$650.0K
Q2 24
$51.5M
$-4.0M
Q1 24
$24.0M
$-9.3M
Free Cash Flow
EYE
EYE
RXST
RXST
Q4 25
$-2.3M
Q3 25
$30.3M
$-1.8M
Q2 25
$42.4M
$-5.9M
Q1 25
$12.0M
$-9.4M
Q4 24
$-1.7M
$-5.1M
Q3 24
$4.1M
$-453.0K
Q2 24
$31.9M
$-5.5M
Q1 24
$4.0M
$-11.3M
FCF Margin
EYE
EYE
RXST
RXST
Q4 25
-6.9%
Q3 25
6.2%
-5.8%
Q2 25
8.7%
-17.6%
Q1 25
2.4%
-24.8%
Q4 24
-0.4%
-12.7%
Q3 24
0.9%
-1.3%
Q2 24
7.1%
-15.9%
Q1 24
0.8%
-38.2%
Capex Intensity
EYE
EYE
RXST
RXST
Q4 25
3.5%
Q3 25
3.4%
1.9%
Q2 25
2.4%
4.6%
Q1 25
4.0%
1.5%
Q4 24
7.3%
2.1%
Q3 24
5.3%
3.1%
Q2 24
4.3%
4.4%
Q1 24
4.1%
6.7%
Cash Conversion
EYE
EYE
RXST
RXST
Q4 25
Q3 25
13.83×
Q2 25
6.22×
Q1 25
2.27×
Q4 24
Q3 24
Q2 24
Q1 24
2.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EYE
EYE

Segment breakdown not available.

RXST
RXST

Rxlal$28.2M86%
LDD$3.0M9%
Service Warranty Service Contracts And Accessories$1.5M4%

Related Comparisons